Misonix Incorporated Appoints Patrick Mcbrayer To Board Of Directors

FARMINGDALE, N.Y., Oct. 7, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today the appointment of Patrick McBrayer to the Company’s Board of Directors effective immediately. Mr. McBrayer succeeds Howard Alliger who has resigned from the Board. The addition of Mr. McBrayer to the Board brings to five the number of independent directors.

With more than 20 years of senior management experience in the healthcare industry, Patrick McBrayer has extensive relevant industry experience to the Misonix Board. Mr. McBrayer currently serves as President and Chief Executive Officer of AxioMed Spine Corporation, a leading, privately-held, developer of next generation technology for degenerative spine conditions.

Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He is also a Founder of Transave Inc., a biotechnology company focused on the site-specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999.

Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology. In both companies, he was responsible for a number of private placements and both companies’ public offerings and led these organizations to dominant market share positions. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market-leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.

A 1974 graduate of the United States Military Academy (West Point), Mr. McBrayer served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. Mr. McBrayer has also served on West Point’s Association of Graduates Board of Trustees.

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, “We are pleased to have Patrick McBrayer join our Board. Pat has extensive healthcare industry experience with emphasis on spinal and orthopedic specialties. His knowledge and leadership will be a great asset to the Board and I look forward to the benefit of his counsel as we continue to make progress in executing on our strategic goals.

“I also want to thank Howard Alliger for his tenure on the Board. Howard was a founder of our Company and we appreciate all of his contributions over the years,” Mr. McManus concluded.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.